Feasibility of ESHAP + G-CSF as Peripheral Blood Hematopoietic Progenitor Cell Mobilisation Regimen in Resistant and Relapsed Lymphoma: a Single-Center Study of 22 Patients

References

• Schwartzberg L S. Peripheral blood stem cell mobilization in the outpatient setting. Peripheral blood stem cell autografts, EW Wunder, PR Henon. Springer-Verlag, Heildelberg 1993; 177–184
   Google Scholar
• Klimo P, Connors J M. An update on the Vancouver experience in the management of advanced Hodgkin's disease treated with the MOPP/ABV hybrid program. Semin Hematol 1988; 25: 34–40, (Suppl 2)
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med; 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Reece D E, Connors J M, Spinelli J. Intensive therapy with cyclophosphamide, carmustine, etoposide +/-cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood; 1994; 83: 1193–1199
   PubMed Web of Science ®Google Scholar
• Chopra R, McMillan A K, Linch D C. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood; 1993; 81: 1737–1746
   Google Scholar
• Bierman P, Anderson J, Vose J. High-dose chemotherapy with autologous hematopoietic rescue for Hodgkin's disease following first relapse after chemotherapy. Proc ASCO; 1993; 12: 366
   Google Scholar
• Reece D, Spinelli J, Barnett M. High-dose cyclophosphamide BCNU, VP16–213 + cisplatin (CBV+P) and autologous stem cell transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy. Blood; 1994; 84: 162abs
   Google Scholar
• Philip T, Armitage J O, Spitzer G. High-dose therapy and autologous bone marrow transplantation after failure to conventional chemotherapy in adults with inermediate-grade or high-grade non-Hodgkin's lymphoma. N Engl J Med; 1987; 316: 1493–1498
   PubMed Web of Science ®Google Scholar
• Vose J M, Anderson J R, Kessinger A. High-dose chemotherapy and autologous hematopoietic stem-celll transplantation for aggressive non-Hodgkin lymphoma. J Clin Oncol; 1993; 11: 1846–1851
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med; 1995; 333: 1540–1545
   PubMed Web of Science ®Google Scholar
• Velasquez W S, Cabanillas F, Salvador P. Effective salvage therapy for lymphoma with cisplatin in combinations with high dose Ara-C and dexamethasone(DHAP). Blood; 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Velasquez W S, McLaughlin P, Tucker F B. ESHAP- an effective chemotherapy regimen in refractory and relapsing lymphoma: a 4-year follow-up study. J Clin Oncol; 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Rodriguez M A, Cabanillas F C, Velasquez W. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP. J Clin Oncol; 1995; 13: 1734–1741
   PubMed Web of Science ®Google Scholar
• Stewart A K, Brandwein J M, Sutcliffe S B. Mini-BEAM as salvage chemotherapy for refractory Hodgkin's disease and non-Hodgkin's lymphoma. Leukemia Lymphoma; 1991; 5: 111–115
   PubMed Web of Science ®Google Scholar
• Chopra R, Linch D C, McMillan A K. Mini-BEAM followed by BEAM and ABMT for very poor risk Hodgkin's disease. Brit J Haematol; 1992; 81: 197–202
   PubMed Web of Science ®Google Scholar
• Colwill R, Crump R, Couture M. Mini-BEAM as salvage therapy for relapsed or refractory Hodgkin's disease before intensive therapy and autologous bone marrow transplantation. J Clin Oncol; 1995; 13: 396–402
   PubMed Web of Science ®Google Scholar
• Tanosaki R, Okamoto S, Hirano T. ESHAP therapy as an efficient regimen for collecting peripheral blood stem cells in relapsed or refractory malignant lymphoma. Book of abstracts of the 1995 Pan-Pacific Lymphoma Conference. 1995, 45
   Google Scholar
• Watts M J, Leverett D, Sullivan A M. A comparision of ESHAP + G-CSF vs cyclophosphamide 1.5g/m2+G-CSF for PBSC mobilisation in pre-treated lymphoma patients: a matched pair analysis. Blood 1996; 88: 396a, (Suppl 1)
   Google Scholar
• Fraser J K, Nishikubo C, Hu J. CD34-positive cell mobilization in patients treated with autologous stem cell transplant for lymphoma: superior harvests in patients with primary refractory disease. Blood 1996; 88: 407a, (Suppl 1)
   Google Scholar
• Petit J, Boqué C, Sarrá J. Feasibility of ESHAP and G-CSF as mobilization regimen for Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: S109, (Suppl 1) abstr P433
   Google Scholar
• McKelvey E M, Gottlieb J A, Haut A. Hydroxyldaunomycin (adriamycin) combination chemotherapy in non-Hodgkin's lymphoma. Proc Am Assoc Cancer Res and ASCO; 1975; 16: 233
   Web of Science ®Google Scholar
• Cancelas J A, Querol S, Canals C. CD34+ cell positive selection from mobilised peripheral blood by an indirect immunomagnetic method: effect of the type of mobilisation and assessment of tumor depletion ability. J Hematother; 1995; 4: 531–538
   PubMedGoogle Scholar
• Pike B, Robinson W A. Human bone marrow colony growth in agar gel. J Cell Physiol; 1971; 76: 77–81
   Web of Science ®Google Scholar
• Sheridan W P, Begley C G, Juttner C A. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet; 1992; 339: 640–644
   PubMed Web of Science ®Google Scholar
• Sheridan W. Cytokine-only approaches to mobilisation of progenitor cells. Cell Therapy, G Morstyn, W Sheridan. Cambridge University Press, New York 1996; 152–157
   Google Scholar
• Dreger P, Marquardt P, Haferlach T. Effective mobilization of peripheral blood progenitor cells with Dexa-BEAM and G-CSF: Timing of harvesting and composition of the leukapheresis product. Brit J Cancer; 1993; 68: 950–957
   PubMed Web of Science ®Google Scholar
• Knauf W U, Koenigsman M P, Notter M. Peripheral blood progenitor cell mobilization with Dexa-BEAM/G-CSF, ether lipid purging, and autologous transplantation after high-dose CBV treatment: a safe and effective regimen in patients with poor risk malignant lymphomas. Leukemia and Lymphoma 1996; 23: 305–311
   PubMed Web of Science ®Google Scholar